| Wissenschaftl. Titel | An Open-Label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants with Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III |
| Erkrankung |
Neuro:
Glioblastom (WHO Grad IV):
Alle Linien
|
| Molekularer Marker |
EGFR |
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (HD) Weiterführende Informationen (NIH) |
erstellt 28.12.2023 Data entry III CCP
geändert 28.12.2023 Data entry III CCP